Safety of the HIV Vaccine 732462 in HIV Infected Subjects Aged 18 to 55 Years Old

NCT00814762 | Completed Phase 1

• 1 other identifier: 112353
• Study Type: interventional
• Target: 41
• Locations: 1 country
• Sites: 6

Brief Summary

The purpose of this research study is to evaluate the safety of GSK Biologicals' investigational HIV vaccine 732462, administered as two doses approximately 1 month apart, in a small group of HIV infected people.

Conditions

AIDS

Keywords

immunogenicity; HIV; reactogenicity; safety; vaccine; HIV Infections

Outcome Measures

Primary Outcomes (7)

• Number of subjects with solicited local symptoms

  Assessed solicited local symptoms were: pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain causing inability to perform usual social and functional activities. Grade 1 redness/swelling = redness/swelling spreading beyond (\>) 50 millimeters (mm) of injection site.

  During a 7-day follow-up period after each vaccination (i.e. the day of vaccination and 6 subsequent days)

• Number of subjects with solicited general symptoms

  Assessed solicited general symptoms were abdominal pain, anorexia, diarrhoea, fatigue, headache, myalgia, nausea, sweating, vomiting and temperature \[oral temperature equal to or above (≥) 37.7 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptoms = symptoms causing inability to perform usual social and functional activities. Grade 3 anorexia = loss of appetite associated with significant weight loss. Grade 3 diarrhoea = bloody diarrhoea or increase of ≥7 stools per 24 hour period, or IV fluid replacement. Grade 3 nausea/vomiting = persistent nausea/vomiting resulting in minimal oral intake for more (\>) than 48 hours/in orthostatic hypotension or aggressive rehydration indicated. Grade 3 temperature = temperature between 39.4- 40.5 °C

  During a 7-day follow-up period after each vaccination (i.e. the day of vaccination and 6 subsequent days)

• Number of subjects with unsolicited Adverse Events (AEs)

  An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

  Day 0-Day 29 after each vaccination

• Number of subjects with Serious Adverse Events (SAEs) and medically attended visits

  Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Medically attended visits include any kind of medical attention such as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason.

  From Screening at Day -42 and up to the additional visit post study end, Month 12

• Number of subjects with study pre-defined Human Immunodeficiency Virus (HIV)-related adverse events

  Study pre-defined HIV-related AEs included: cluster of differentiation-4 (CD4) count decrease \[(≥)25% post vaccination\], viral load increase \[(≥)50 copies per (/) milliliter (mL) of HIV ribonucleic acid (RNA) post-vaccination, for cohort A and at least 0.5 log post-vaccination for cohort B\], initiation of Highly Active Anti-Retroviral Therapy (HAART) for cohort B, or changes in HAART for cohort A, abnormal biochemistry and haematology parameters.

  From Day 0 to study end at Month 12

• Number of subjects presenting abnormal biochemical and haematological values (any and grade ≥ 3)

  Assessed biochemical and haematological parameters included: Absolute neutrophil count (ANC), Haemoglobin (Hgb), Partial Thromboplastin Time (PTT), Platelets decreased (PLT/D), WBC decreased (WBC/D), Albumin serum low (ALB/SL), Alkaline Phosphatase (ALP), Alanine aminotransferase (SGPT), Aspartate aminotransferase (SGOT), Bilirubin Total (BL/T), Creatinine (CRT), Potassium serum high (K/SH), Potassium serum low (K/SL), Sodium serum high (Na/SH), Sodium serum low (NA/SL), Uric acid (UA).

  From Day 0 to study end at Month 12

• Time to initiation of HAART therapy (for treatment-naïve HIV-infected subjects) or change in HAART therapy (for HIV-infected subjects receiving HAART)

  Time to HAART initiation and/or HAART changes was expressed in days from administration of first dose.

  From Day 0 to Month 12

Secondary Outcomes (3)

• CD4 count and change of CD4 count from baseline

  From Day 0 to Month 12

• Viral load and change in viral load from baseline

  From Day 0 to Month 12

• Cluster of differentiation 40 ligand (CD40L+) CD4+ T-cell-mediated immune response (as measured by ICS)

  Months 0, 4, 12 and at Day 44

Study Arms (2)

HIV 732462 Group

EXPERIMENTAL

Subjects received 2 doses of the HIV Vaccine 732462 into the deltoid muscle of the dominant arm, on a 0, 1 Month schedule.

Biological: HIV Vaccine 732462

Placebo Group

PLACEBO COMPARATOR

Subjects received 2 doses of the placebo vaccine into the deltoid muscle of the dominant arm, on a 0, 1 Month schedule.

Biological: Placebo vaccine

Interventions

HIV Vaccine 732462 BIOLOGICAL

Two doses reconstituted adjuvanted vaccine, injected intramuscularly, at an interval of approximately one month.

HIV 732462 Group

Placebo vaccine BIOLOGICAL

Two doses of placebo, injected intramuscularly, at an interval of approximately one month

Placebo Group

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• All subjects must satisfy the following criteria at screening and before vaccination:
• A male or female, aged between and including 18-55 years at the time of first vaccination.
• Known to be HIV-1 infected and under care of an HIV physician for a minimum of 6 months. However, subjects who initially presented with primary HIV infection need to have been diagnosed and under care for 12 months.
• Written informed consent obtained from the subject prior to any study procedure.
• Subjects who the investigator believes that they can and will comply with the requirements of the protocol.
• If the subject is female, she must be of non-childbearing potential, or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions throughout the duration of the study.
• CD4 count ≥ 450 cells per mm³
• Stable on highly active antiretroviral therapy (HAART) for at least one year.
• Undetectable viral load
• HAART-naïve (never received anti-retrovirals after HIV diagnosis)
• VL 5000-80000 copies/mL at screening
• Commencement of HAART is not expected based on current assessment within next year.

You may not qualify if:

• The following criteria should be checked at the time of screening and before vaccination. If any apply, the subject must not be included in the study:
• Infection with HIV-2
• Had an AIDS defining illness (CDC Classification).
• Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding the first dose of study vaccine/placebo, or planned use of any investigational or non-registered product other than the study vaccine during the study period.
• Drug therapy with immunomodulators or steroids within the three months preceding the first dose of study vaccine/placebo or planned administration during the study period
• Administration of immunoglobulins and/ or any blood products within the three months preceding the first dose of study vaccine/placebo or planned administration during the study period.
• Planned administration of a vaccine not foreseen by the study protocol during the period starting 30 days before the first dose of study vaccine/placebo and ending at Month 4 It is recommended that the vaccination history of all subjects has been reviewed with their health care provider and that they have been encouraged to be fully vaccinated according to their country vaccination schedule for HIV- infected persons before enrolment into this study.
• Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
• Any previous vaccination or immunotherapy against HIV.
• History of immune reconstitution disease when commencing antiretroviral therapy (for HIV-infected subjects receiving HAART)
• A family history of hereditary immunodeficiency.
• History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
• Acute or chronic, clinically relevant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.
• Pregnant or lactating female.
• Female planning to become pregnant or planning to discontinue contraceptive precautions.

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (6)

GSK Investigational Site

Erlangen, Bavaria, 91054, Germany

Location

GSK Investigational Site

Munich, Bavaria, 80335, Germany

Location

GSK Investigational Site

Cologne, North Rhine-Westphalia, 50937, Germany

Location

GSK Investigational Site

Berlin, 12157, Germany

Location

GSK Investigational Site

Hamburg, 20099, Germany

Location

GSK Investigational Site

Hamburg, 20246, Germany

Location

Related Publications (1)

• Harrer T, Plettenberg A, Arasteh K, Van Lunzen J, Fatkenheuer G, Jaeger H, Janssens M, Burny W, Collard A, Roman F, Loeliger A, Koutsoukos M, Bourguignon P, Lavreys L, Voss G. Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study. Vaccine. 2014 May 7;32(22):2657-65. doi: 10.1016/j.vaccine.2013.10.030. Epub 2013 Oct 19.

  PMID: 24144472 DERIVED

Related Links

• Results for study 112353 can be found on the GSK Clinical Study Register

MeSH Terms

Conditions

Acquired Immunodeficiency Syndrome; HIV Infections

Condition Hierarchy (Ancestors)

Blood-Borne Infections; Communicable Diseases; Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Slow Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 23, 2008
• First Posted: December 25, 2008
• Study Start: February 3, 2009
• Primary Completion: August 18, 2010
• Study Completion: August 18, 2010
• Last Updated: June 18, 2018

Record last verified: 2018-06

Locations

DE (6)